JP2024542142A - 新規ポリペプチド - Google Patents

新規ポリペプチド Download PDF

Info

Publication number
JP2024542142A
JP2024542142A JP2024526902A JP2024526902A JP2024542142A JP 2024542142 A JP2024542142 A JP 2024542142A JP 2024526902 A JP2024526902 A JP 2024526902A JP 2024526902 A JP2024526902 A JP 2024526902A JP 2024542142 A JP2024542142 A JP 2024542142A
Authority
JP
Japan
Prior art keywords
polypeptide
domain
mutation
mutations
ckappa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024526902A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024542142A5 (cg-RX-API-DMAC7.html
Inventor
ローラ・フォン・シャンツ
バルナバス・ネシガ
マティアス・レヴィン
アンナ・サール
Original Assignee
アリゲーター・バイオサイエンス・アーベー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2204539.7A external-priority patent/GB202204539D0/en
Priority claimed from GBGB2212801.1A external-priority patent/GB202212801D0/en
Application filed by アリゲーター・バイオサイエンス・アーベー filed Critical アリゲーター・バイオサイエンス・アーベー
Publication of JP2024542142A publication Critical patent/JP2024542142A/ja
Publication of JP2024542142A5 publication Critical patent/JP2024542142A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2024526902A 2021-11-05 2022-11-04 新規ポリペプチド Pending JP2024542142A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB2115925.6 2021-11-05
GB202115925 2021-11-05
GB2204539.7 2022-03-30
GBGB2204539.7A GB202204539D0 (en) 2022-03-30 2022-03-30 Novel peptides
GBGB2212801.1A GB202212801D0 (en) 2022-09-02 2022-09-02 Novel peptides
GB2212801.1 2022-09-02
PCT/EP2022/080860 WO2023079101A2 (en) 2021-11-05 2022-11-04 Novel polypeptides

Publications (2)

Publication Number Publication Date
JP2024542142A true JP2024542142A (ja) 2024-11-13
JP2024542142A5 JP2024542142A5 (cg-RX-API-DMAC7.html) 2025-11-13

Family

ID=84329469

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2024526902A Pending JP2024542142A (ja) 2021-11-05 2022-11-04 新規ポリペプチド
JP2024526901A Pending JP2024543043A (ja) 2021-11-05 2022-11-04 新規ペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024526901A Pending JP2024543043A (ja) 2021-11-05 2022-11-04 新規ペプチド

Country Status (9)

Country Link
US (4) US20260001961A1 (cg-RX-API-DMAC7.html)
EP (2) EP4426733A2 (cg-RX-API-DMAC7.html)
JP (2) JP2024542142A (cg-RX-API-DMAC7.html)
KR (2) KR20240099410A (cg-RX-API-DMAC7.html)
AU (1) AU2022381977A1 (cg-RX-API-DMAC7.html)
CA (1) CA3237463A1 (cg-RX-API-DMAC7.html)
IL (1) IL312556A (cg-RX-API-DMAC7.html)
MX (1) MX2024005508A (cg-RX-API-DMAC7.html)
WO (2) WO2023079102A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20260001961A1 (en) * 2021-11-05 2026-01-01 Alligator Bioscience Ab Novel polypeptides
JP2026515781A (ja) * 2023-04-13 2026-05-19 アリゲーター・バイオサイエンス・アーベー 併用療法
CN117924468B (zh) * 2023-12-08 2024-09-20 南京大学 一种靶向登革热病毒ns1蛋白纳米抗体的制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
LT2691417T (lt) 2011-03-29 2018-10-25 Roche Glycart Ag Antikūno fc variantai
GB201115280D0 (en) * 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
CA2980189A1 (en) * 2015-04-24 2016-10-27 Genentech, Inc. Multispecific antigen-binding proteins
CA3049791A1 (en) * 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
EP3898681A2 (en) * 2018-12-17 2021-10-27 Alligator Bioscience AB Polypeptides
GB201820556D0 (en) 2018-12-17 2019-01-30 Alligator Bioscience Ab Novel polypeptides
AU2020357944A1 (en) * 2019-09-30 2022-03-31 Adimab, Llc CH1 domain variants engineered for preferential light chain pairing and multispecific antibodies comprising the same
EP4048701A4 (en) 2019-10-23 2024-05-29 Lyvgen Biopharma Holdings Limited Anti-cd40 binding molecules and bi-specific antibodies comprising such
KR20220147583A (ko) * 2020-01-09 2022-11-03 바이오뮤넥스 파마슈티컬스 Mait 및 종양 세포 둘 모두에 결합하는 다중특이적 항체
US20260001961A1 (en) * 2021-11-05 2026-01-01 Alligator Bioscience Ab Novel polypeptides

Also Published As

Publication number Publication date
WO2023079101A3 (en) 2023-06-15
JP2024543043A (ja) 2024-11-19
IL312556A (en) 2024-07-01
US20260001961A1 (en) 2026-01-01
KR20240099410A (ko) 2024-06-28
AU2022381977A1 (en) 2024-05-23
KR20240114794A (ko) 2024-07-24
US11873348B2 (en) 2024-01-16
EP4426738A2 (en) 2024-09-11
US20260146107A1 (en) 2026-05-28
WO2023079101A2 (en) 2023-05-11
EP4426733A2 (en) 2024-09-11
US20240117074A1 (en) 2024-04-11
US12448465B2 (en) 2025-10-21
US20230312754A1 (en) 2023-10-05
MX2024005508A (es) 2024-09-18
CA3237463A1 (en) 2023-05-11
WO2023079102A2 (en) 2023-05-11
WO2023079102A3 (en) 2023-06-15

Similar Documents

Publication Publication Date Title
JP7069261B2 (ja) Cd73特異的結合分子及びその使用
KR102427192B1 (ko) 항-인간 4-1bb 항체 및 그의 용도
JP7425604B2 (ja) 抗ctla4-抗pd-1二機能性抗体、その医薬組成物および使用
CN110869388B (zh) 用于肿瘤特异性细胞消耗的Fc优化的抗CD25
JP6858779B2 (ja) キメラ及びヒト化抗ヒトctla4モノクローナル抗体ならびにその使用
JP6847037B2 (ja) 抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
US20200407446A1 (en) Bispecific antibody for icos and pd-l1
KR20200131286A (ko) 종양 특이적 세포 고갈에 대한 항-cd25
JP7688579B2 (ja) 抗trem2抗体の使用方法
US12570759B2 (en) Polypeptides
KR20220032642A (ko) 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
US20260001961A1 (en) Novel polypeptides
CN113677703A (zh) 多肽
KR20200041835A (ko) 재조합 이중특이적 항체
JP2023525423A (ja) Prameに特異的に結合する抗原結合タンパク質
KR20240006519A (ko) 항-siglec 조성물 및 이의 용도
AU2022381918A1 (en) Bispecific cd16a binders
CN118434767A (zh) 新型多肽
RU2839380C1 (ru) Fc-оптимизированные антитела к cd25 для истощения опухолеспецифических клеток
TW202607042A (zh) 多特異性抗原結合蛋白
TW202544031A (zh) 抗tigit/抗pd-l1雙特異性抗體及其用途
WO2025264856A1 (en) Antibody combinations for macrophage stimulation
HK40066344B (en) Ox40/pd-l1 bispecific antibody
HK40066344A (en) Ox40/pd-l1 bispecific antibody
EA049996B1 (ru) Антитело к siglec-10 (варианты)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251104

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251104